StockData

IDEAYA Biosciences vs Puma Biotechnology

IDYA and PBYI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IDYA and PBYI compare

IDEAYA Biosciences is the larger company, worth 7.2 times as much as Puma Biotechnology ($2.6B against $369M).

Puma Biotechnology keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −74.8% at IDEAYA Biosciences.

Puma Biotechnology scores higher on the StockData Score (14 against 10 for IDEAYA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIDYAPBYI
Size and price
Market cap$2.6B$369M
Share price$27.40$7.14
Change, 1 year−14.7%46.0%
Change, 5 years15.1%121%
Beta (5Y)1.111.32
Employees145179
StockData Score
Total score1014 (better)
Valuation score12 (better)
Growth score12 (better)
Performance score25 (better)
Health score6 (better)5
Dividend score00
Valuation
P/E–13.7×
P/S11.3×1.6× (better)
P/B2.2× (better)2.7×
EV/EBITDA–6.9×
P/FCF–9.0×
FCF yield−4.3%11.2% (better)
Fair value$29.50$8.84
Margin of safety7.1%19.2% (better)
Growth
Revenue growth (TTM)–−2.9%
Revenue growth, 5Y average62.1% (better)0.29%
Net income growth (TTM)–−44.9%
EPS growth (TTM)–−46.9%
Profitability
Gross margin–74.8%
Operating margin−92.7%13.2% (better)
Net margin−74.8%11.6% (better)
FCF margin−48.6%17.8% (better)
Return on equity−16.2%22.0% (better)
Return on invested capital−51.9%42.7% (better)
Financial health
Debt / equity0.000.00
Net debt / EBITDA–−2.12
Interest coverage–8.6×
Current ratio10.45 (better)2.91
Altman Z-score13.65 (better)−2.90
Piotroski F-score48 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions106%74.9%
Held by insiders0.83%18.9%
Insider net buying, 12 months$281K (better)−$2.1M
Short interest, % of float8.6%10.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.